Cannabis and Warfarin (Coumadin)
Generic: warfarin
Brand names: Coumadin, Jantoven
Important Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice. Do not start, stop, or modify your use of Warfarin or cannabis without consulting your doctor or pharmacist. If you experience adverse effects, seek immediate medical attention. Individual responses to drug combinations vary significantly.
Overview
Warfarin (Coumadin) is a vitamin K antagonist anticoagulant prescribed to prevent and treat blood clots, strokes, and pulmonary embolism. This combination is rated HIGH RISK because CBD potently inhibits CYP2C9, the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. This interaction can substantially increase warfarin blood levels and elevate the International Normalized Ratio (INR), increasing the risk of serious or potentially fatal bleeding events. Published case reports have documented clinically significant INR elevation in patients who added CBD products to their warfarin regimen. The warfarin-cannabis interaction is particularly dangerous because warfarin has a narrow therapeutic index — the difference between a therapeutic dose and a dangerous dose is small. Even modest changes in warfarin metabolism can shift the INR from the target range (typically 2.0–3.0) to dangerously elevated levels. Unlike many drug interactions where the consequences are uncomfortable but not immediately life-threatening, uncontrolled warfarin elevation can cause intracranial hemorrhage, gastrointestinal bleeding, and other hemorrhagic emergencies. Patients on warfarin should exercise extreme caution with any cannabis product, particularly those containing CBD. This information is for educational purposes only. Consult your healthcare provider.
How They Interact
Warfarin is a racemic mixture of R- and S-enantiomers, with S-warfarin being 3–5 times more potent than R-warfarin. S-warfarin is metabolized primarily by CYP2C9, while R-warfarin is metabolized by CYP1A2, CYP3A4, and CYP2C19. CBD potently inhibits CYP2C9 (Ki ~0.9–2.7 μM, depending on the study), directly impeding the clearance of the more pharmacologically active S-warfarin enantiomer. This leads to elevated S-warfarin levels and disproportionate anticoagulant effect, manifesting as a rising INR. CBD also inhibits CYP3A4 and CYP2C19, which may further reduce clearance of R-warfarin. The net effect is significantly enhanced anticoagulation and increased bleeding risk. THC is metabolized by CYP2C9 and may also compete with warfarin for enzymatic clearance, adding a pharmacokinetic component even from THC-dominant products.
Cannabinoid-Specific Interactions
| Cannabinoid | Interaction with Warfarin |
|---|---|
| CBD | CBD potently inhibits CYP2C9, the enzyme that clears the active S-warfarin enantiomer. This is the most clinically dangerous aspect of the interaction, as it directly increases anticoagulant potency and bleeding risk. Published case reports document INR increases of 50–200% after initiating CBD in warfarin-stabilized patients. This interaction requires immediate medical attention. |
| THC | THC is also a CYP2C9 substrate and may compete with warfarin for enzymatic metabolism, contributing to elevated warfarin levels. Additionally, THC can cause tachycardia and blood pressure changes, which may be problematic in patients with cardiovascular conditions requiring anticoagulation. |
| CBG | Cannabigerol's CYP2C9 interaction profile is not well characterized, but preliminary data suggest it may also have inhibitory activity. Given the critical importance of stable warfarin metabolism, any cannabinoid with potential CYP2C9 effects should be considered risky in warfarin-treated patients. |
Symptoms to Watch For
- ⚠Unusual bruising or bruises that enlarge spontaneously
- ⚠Prolonged bleeding from cuts or gum bleeding
- ⚠Blood in urine (pink or red) or stools (dark, tarry, or red)
- ⚠Unexplained nosebleeds
- ⚠Severe headache or vision changes (may indicate intracranial bleeding — emergency)
Recommendations
- 1Inform your anticoagulation clinic or prescribing physician immediately if you start, stop, or change the dose of any cannabis product.
- 2If you use cannabis while on warfarin, your INR must be monitored more frequently — at least weekly until stable.
- 3Seek emergency medical care for any signs of unusual bleeding, severe headache, confusion, or blood in urine or stool.
- 4Avoid high-dose CBD products entirely while on warfarin, as the CYP2C9 inhibition is potent and dose-dependent.
- 5Do not adjust your warfarin dose on your own — all dose changes should be directed by your healthcare provider based on INR results.
Research Summary
The warfarin-CBD interaction is one of the best-documented cannabinoid drug interactions. A landmark 2017 case report in Epilepsy & Behavior documented a patient on warfarin who initiated Epidiolex (pharmaceutical CBD) and experienced an INR increase from 2.5 to 8.4, requiring warfarin dose reduction. Subsequent case series have confirmed this finding, with consistent reports of INR elevation following CBD initiation. In vitro studies confirm CBD's potent CYP2C9 inhibition, with Ki values in the sub-micromolar to low micromolar range. A 2020 pharmacokinetic modeling study predicted that CBD doses as low as 5 mg/day could produce measurable effects on warfarin metabolism in CYP2C9 poor metabolizers. The FDA label for Epidiolex includes a specific warning about the warfarin interaction. Clinical pharmacology guidelines uniformly recommend increased INR monitoring when cannabinoids are used with warfarin. This information is for educational purposes only. Consult your healthcare provider.
Frequently Asked Questions
Can CBD cause dangerous bleeding if I'm on warfarin?
Yes. CBD inhibits CYP2C9, the enzyme that metabolizes warfarin's active component. This can raise your INR significantly, increasing the risk of serious bleeding, including potentially life-threatening intracranial or gastrointestinal hemorrhage. Case reports have documented INR increases from safe ranges to dangerously elevated levels after CBD initiation.
How quickly can CBD affect my INR on warfarin?
INR changes can occur within days of starting CBD, though the full effect may take 1–2 weeks to manifest as warfarin has a long half-life (20–60 hours). INR should be checked within a few days of starting, stopping, or changing the dose of any CBD product, and then monitored weekly until stable.
Is THC-only cannabis safer than CBD with warfarin?
THC has less direct CYP2C9 inhibition than CBD, making the pharmacokinetic interaction somewhat less pronounced. However, THC is itself a CYP2C9 substrate and may still affect warfarin metabolism through competitive inhibition. No cannabis product should be considered safe with warfarin without medical monitoring.
Should I stop cannabis if I need to start warfarin?
You should discuss this with your anticoagulation provider. If you choose to continue cannabis use, your INR will need frequent monitoring, and your warfarin dose may need adjustment. If you discontinue cannabis after your warfarin dose has been adjusted down to compensate, your INR may drop dangerously low, reducing anticoagulation protection. Any change in cannabis use requires INR re-evaluation.